One Capital Management LLC Grows Holdings in Ionis Pharmaceuticals, Inc. $IONS

One Capital Management LLC boosted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 26.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,121 shares of the company’s stock after purchasing an additional 9,695 shares during the quarter. One Capital Management LLC’s holdings in Ionis Pharmaceuticals were worth $3,649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Grandfield & Dodd LLC raised its position in Ionis Pharmaceuticals by 0.4% in the 4th quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock valued at $2,992,000 after purchasing an additional 146 shares during the last quarter. Wedmont Private Capital raised its position in Ionis Pharmaceuticals by 3.2% in the 4th quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock valued at $460,000 after purchasing an additional 173 shares during the last quarter. Prospera Financial Services Inc raised its position in Ionis Pharmaceuticals by 3.9% in the 4th quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock valued at $376,000 after purchasing an additional 178 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in Ionis Pharmaceuticals by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock valued at $3,176,000 after purchasing an additional 301 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Ionis Pharmaceuticals by 37.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,137 shares of the company’s stock valued at $90,000 after purchasing an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Down 3.2%

Shares of Ionis Pharmaceuticals stock opened at $72.97 on Wednesday. The company has a market cap of $12.06 billion, a P/E ratio of -35.25 and a beta of 0.37. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10. Ionis Pharmaceuticals, Inc. has a one year low of $33.95 and a one year high of $86.74. The firm has a fifty day moving average of $74.70 and a two-hundred day moving average of $77.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. The company had revenue of $246.09 million during the quarter, compared to the consensus estimate of $195.57 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. Ionis Pharmaceuticals’s quarterly revenue was up 86.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.93) EPS. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.76 earnings per share for the current year.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 126,670 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $75.20, for a total transaction of $9,525,584.00. Following the completion of the transaction, the chief executive officer owned 242,662 shares in the company, valued at approximately $18,248,182.40. This represents a 34.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth L. Hougen sold 215,048 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $72.40, for a total transaction of $15,569,475.20. Following the transaction, the executive vice president owned 92,832 shares of the company’s stock, valued at approximately $6,721,036.80. The trade was a 69.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 456,298 shares of company stock worth $33,713,865 in the last 90 days. Corporate insiders own 1.81% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on IONS. Canaccord Genuity Group began coverage on shares of Ionis Pharmaceuticals in a research report on Monday, April 20th. They issued a “buy” rating and a $110.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 21st. Citigroup began coverage on shares of Ionis Pharmaceuticals in a research report on Monday, May 18th. They issued a “buy” rating and a $115.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $125.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 27th. Finally, Piper Sandler upped their price target on shares of Ionis Pharmaceuticals from $87.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $100.90.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.